Search
for
Sort by
Research 30 of 1000+
- Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review
- Cutaneous manifestations associated with immune checkpoint inhibitors
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
- Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
- Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Cutaneous lupus erythematosus induced by tislelizumab
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Dermatologic Adverse Events from Cancer Treatments
- A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment
- Development of PEGylated Liposomes